KFDA vs FDA vs EU: Cosmetic Safety Standards for K-Beauty Brands Selling Globally in 2026

By the ALTA MEET editorial team | K-beauty ODM consulting

If you are planning to sell a Korean-made skincare line in the United States, the European Union, and South Korea itself, you are not dealing with one regulatory system. You are dealing with three, and each one defines "safe cosmetic" differently. The differences are not academic. They determine what your Korean ODM partner tests for, what paperwork you file before a single unit ships, and how much of your launch budget goes to compliance instead of inventory. This guide puts the three systems next to each other so you can plan a multi-market launch without discovering a $10,000 surprise six weeks before your go-live date.

What Each Regulator Actually Oversees

Before comparing specific rules, it helps to know who is in charge and what authority they hold.

Korea's MFDS (Ministry of Food and Drug Safety) oversees all cosmetics manufactured or sold in South Korea under the Cosmetics Act. MFDS splits cosmetics into two categories: general cosmetics and functional cosmetics. General cosmetics require notification only. Functional cosmetics, which include products making claims about whitening, anti-wrinkle effects, UV protection, or hair loss prevention, require a separate review and approval process with clinical efficacy data. This distinction has no equivalent in the US or EU systems. If your Korean ODM formulates a product with functional claims for the domestic Korean market, expect a longer timeline and higher cost than if the same formula ships to the US or EU with different claim language.

The US FDA regulates cosmetics under the Federal Food, Drug, and Cosmetic Act, now significantly expanded by MoCRA (Modernization of Cosmetics Regulation Act of 2022, Public Law 117-328). Before MoCRA, the US had the lightest regulatory touch of the three markets: no pre-market approval, no mandatory registration, and voluntary adverse event reporting. MoCRA changed that. Since December 2023, facility registration and product listing through the Cosmetics Direct portal are mandatory. Adverse event reporting is now required within 15 business days. Safety substantiation must exist for every marketed product. However, the FDA still does not require pre-market review of cosmetic formulations.

The European Commission enforces Regulation (EC) No 1223/2009, which remains the most prescriptive of the three frameworks. Every cosmetic product sold in the EU must have a designated Responsible Person (RP) established within the EU. Before a product reaches the market, it must undergo a Cosmetic Product Safety Report (CPSR) conducted by a qualified safety assessor, and the product must be notified through the Cosmetic Products Notification Portal (CPNP). There is no grace period. Products found on the EU market without CPNP notification face immediate withdrawal.Pre-Market Requirements: Who Checks What Before You Sell

This is where the three systems diverge most sharply, and where your timeline and budget feel the impact.

Korea (MFDS): General cosmetics require a product notification that includes ingredient lists, labeling, and manufacturing facility information. The process typically takes two to four weeks. Functional cosmetics require a formal review application with efficacy test data, safety data, and formulation details. Review periods range from three to six months, and the process often costs $8,000 to $15,000 when you include the required clinical testing for whitening or anti-wrinkle claims. Animal testing is banned for cosmetics in South Korea, so all safety and efficacy data must come from in vitro or human clinical studies.

United States (FDA/MoCRA): There is no pre-market review. You do not submit your formula to the FDA for approval before selling. However, you must register your manufacturing facility (Form FDA 5066), list your products (Form FDA 5067), and maintain adequate safety substantiation. The safety substantiation requirement, while not requiring FDA submission, means you need a Product Safety Substantiation Dossier (PSSD) on file that demonstrates your product is safe under intended use conditions. Facility registration renewals are biennial, with the first renewal cycle hitting mid-2026 for facilities that registered by the July 2024 deadline. Small businesses with less than $1 million in average annual sales are exempt from facility registration and product listing, but not from safety substantiation or adverse event reporting.

European Union (EC 1223/2009): The most demanding pre-market process. You need a Responsible Person in the EU, a completed CPSR (which costs $350 to $3,000 depending on product complexity and the assessor), a Product Information File (PIF) that must be maintained for 10 years after the last batch, and a CPNP notification before any unit is sold. Products containing nanomaterials require CPNP notification six months before market placement. The RP takes legal liability for compliance, which is why EU RP services cost $400 to $600 per year on top of per-product fees.

The practical difference: A Korean ODM can manufacture your product and have it ready for the US market with relatively light paperwork (facility registration, product listing, safety substantiation). The same product going to the EU needs a safety assessor, a Responsible Person, a PIF, and CPNP notification. Going to Korea's domestic market with functional claims adds clinical testing. A three-market launch from a single Korean ODM run is possible, but the regulatory costs and timelines stack, not overlap.Contaminant and Microbial Limits Side by Side

All three regulators set limits on heavy metals and microbial contamination, but the numbers are not identical.

Heavy metals (as unintentional contaminants under GMP):

For lead, the FDA's draft guidance recommends a maximum of 10 ppm in cosmetics. The EU treats lead as a prohibited substance under Annex II of Regulation 1223/2009, but allows trace amounts that are technically unavoidable under GMP, with industry guidance suggesting limits around 10 mg/kg. Korea's MFDS sets a limit of 20 ppm for lead in cosmetics. For mercury, all three systems effectively prohibit intentional use. The EU sets a trace limit of approximately 1 mg/kg. The FDA has a longstanding action level of 1 ppm for mercury in cosmetics. Korea similarly prohibits mercury with trace allowances. For arsenic, Korea's MFDS sets a limit of 10 ppm, while the EU industry guidance is around 2 mg/kg and the FDA does not have a formal limit but tests for it.

Microbial limits:

ISO 17516:2014 serves as the baseline reference for all three markets. The standard sets total aerobic mesophilic count limits at 1,000 CFU/g (10 to the third) for general products, and 100 CFU/g (10 to the second) for products used around the eyes, on mucous membranes, or on children under three. Specific pathogens (Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans) must be absent in 0.1g or 0.1mL. Korea's MFDS and the EU both reference ISO 17516 directly. The US FDA references USP chapters 61 and 62 for microbial enumeration and specified organism testing, which align closely with ISO 17516 limits but use different testing methodology language.

What this means for founders: If your Korean ODM tests to ISO 17516 and ISO 22716 (GMP) standards, you are largely covered across all three markets for microbial compliance. Heavy metal testing results from Korea will generally satisfy US and EU requirements, but check the specific limits because Korea's lead threshold (20 ppm) is more lenient than the FDA's recommended 10 ppm and EU's 10 mg/kg guidance. Ask your ODM partner whether their internal specs match the tightest standard across your target markets, not just the Korean domestic standard.Registration, Listing, and Notification: The Paperwork Comparison

Each market requires you to tell the regulator that your product exists before (or shortly after) you start selling. The mechanisms differ.

Korea (MFDS): General cosmetics: product notification through the MFDS electronic system, including ingredient list (INCI), product category, manufacturer details, and labeling samples. Functional cosmetics: formal application with efficacy data and safety dossier. Manufacturing facilities in Korea must hold a Cosmetic Manufacturing Business Registration. Foreign brands importing into Korea must designate a local Korean importer who files the notification.

United States (FDA/MoCRA): Facility registration through Cosmetics Direct (Form FDA 5066), requiring an FEI (FDA Establishment Identifier) number. Product listing (Form FDA 5067) with full ingredient list in SPL format. Both domestic and foreign facilities manufacturing cosmetics for the US market must register. Product listing updates are due annually. The system is relatively straightforward compared to the EU, but the SPL format for ingredient submission is technical and often requires regulatory consulting support.

European Union (EC 1223/2009): CPNP notification is mandatory before market placement. The notification includes product category, name, Responsible Person details, country of origin, and frame formulation or exact composition. The EU also requires reporting of Serious Undesirable Effects (SUEs) through a separate system. Unlike the US, where the manufacturer registers, in the EU the Responsible Person submits the notification and holds legal accountability.

Cost comparison for a single SKU entering all three markets:

Korea notification (general cosmetic): typically $500 to $1,500 through a regulatory consultant. Korea functional cosmetic review: $8,000 to $15,000 including clinical testing. US MoCRA compliance (facility registration + product listing + safety substantiation): typically $4,000 to $12,000 total when using a US Agent and regulatory consultant. EU compliance (RP + CPSR + CPNP + PIF): typically $3,000 to $15,000, depending on product complexity and whether you need a new RP relationship.

For a founder launching one SKU into all three markets, total regulatory costs commonly range from $7,500 (general cosmetic, lean approach) to $42,000 (functional cosmetic in Korea, full consulting in US and EU). These numbers do not include product liability insurance, which is effectively mandatory in the EU and increasingly expected in the US.When Things Go Wrong: Adverse Event Reporting and Recalls

Korea (MFDS): Cosmetic businesses must report serious adverse events to MFDS. Functional cosmetics are subject to stricter post-market surveillance. MFDS can order recalls, suspensions, or label corrections. The recall system includes three classes based on severity.United States (FDA/MoCRA): MoCRA introduced mandatory serious adverse event reporting within 15 business days of receiving the report. Records must be maintained for six years (three years for small businesses). This was the single biggest change from the pre-MoCRA era, when adverse event reporting was voluntary. The FDA can now also order mandatory recalls of cosmetics, a power it did not previously hold.

European Union (EC 1223/2009): The Responsible Person must report Serious Undesirable Effects (SUEs) to the competent authority of the member state where the effect occurred. The RP must also make the SUE information available to competent authorities of other member states upon request. Competent authorities can order product withdrawal or recall. The EU system has been in place since 2013 and is well-established, with over a decade of enforcement precedent.

The practical takeaway: If you are manufacturing in Korea and selling into all three markets, you need three separate adverse event reporting workflows. Your Korean ODM partner handles Korea-side reporting. Your US Agent or Responsible Person handles FDA reporting. Your EU Responsible Person handles SUE reporting. Set up these reporting pathways before launch, not after your first complaint.Test paragraph here.“I’m Liz, and I run ALTA MEET from Manhattan, NYC. One of the first things I walk founders through is mapping out their regulatory costs by market, not by product. The per-product numbers look manageable until you multiply by three markets and realize your compliance budget just doubled your first production run. If you want a quick 15-minute gut-check on whether your multi-market plan makes financial sense before you sign an ODM contract, I will give you that time free.”Email Liz: liz@altameet.com | General inquiries: partnerships@altameet.comWhat a Multi-Market Strategy Actually Costs: Three Scenarios

Knowing the regulatory frameworks is useful. Knowing what they cost in practice is what changes your budget spreadsheet.

Scenario 1: US-only launch (leanest path). Facility registration and product listing through a US Agent: $500 to $2,000 per year. Safety substantiation dossier: $1,500 to $5,000. Labeling review: $300 to $800 per SKU. Total per SKU: roughly $2,300 to $7,800. This is the lowest barrier to entry of the three markets.

Scenario 2: US + EU launch. Add to Scenario 1: EU Responsible Person retainer ($400 to $600 per year), CPSR ($350 to $3,000 per product), PIF preparation ($500 to $2,000), and CPNP notification (free, but labor-intensive). Total per SKU for both markets: roughly $3,500 to $13,400. The EU adds $1,200 to $5,600 per SKU on top of US costs.Scenario 3: US + EU + Korea domestic (functional cosmetic). Add to Scenario 2: MFDS functional cosmetic review ($8,000 to $15,000 including clinical testing), Korean labeling and notification ($500 to $1,500). Total per SKU across all three markets: roughly $12,000 to $29,900. If you are making anti-wrinkle or whitening claims in Korea, the MFDS clinical testing is the single largest line item.

These ranges are based on what we see in 2026 quotations from regulatory consulting partners across all three markets. Your actual costs depend on product complexity, the number of active claims, whether your manufacturing facility already holds relevant certifications (ISO 22716 is effectively required for all three markets), and whether you can bundle multiple SKUs into a single regulatory submission.Working With ALTA MEET

ALTA MEET is a New York-based K-beauty ODM consulting partner that works directly with Korean manufacturers on behalf of indie beauty founders. We help founders plan multi-market launches from a single Korean ODM production run, including regulatory pathway mapping for the US, EU, and Korean domestic markets.

If your Korean ODM contract is coming up and you have not mapped out your regulatory costs by market, a 15-minute call with our team can save you weeks of back-and-forth.

Email us: partnerships@altameet.com | Visit: altameet.comRelated reading on ALTA MEET:

How to Register Korean Cosmetics with the FDA Under MoCRA

How Much Does It Cost to Manufacture Cosmetics in Korea?

FDA Korean Skincare Import GuideKey Takeaways

1. The US (FDA/MoCRA), EU (EC 1223/2009), and Korea (MFDS Cosmetics Act) each define cosmetic safety differently, and compliance for one market does not automatically cover the others.

2. Korea is the only system that splits cosmetics into general and functional categories, with functional cosmetics requiring clinical efficacy data and a separate review process costing $8,000 to $15,000.

3. The EU requires the most pre-market documentation: a Responsible Person, a CPSR, a PIF, and CPNP notification before any unit is sold.

4. The US under MoCRA now requires facility registration, product listing, safety substantiation, and mandatory adverse event reporting within 15 business days, but still does not require pre-market formula review.5. Heavy metal thresholds differ: Korea allows up to 20 ppm lead, while FDA guidance recommends 10 ppm and EU guidance suggests approximately 10 mg/kg. Ask your ODM to test to the tightest standard across your target markets.

6. Microbial testing to ISO 17516 and manufacturing under ISO 22716 GMP covers the baseline for all three markets.

7. A single-SKU launch into all three markets can cost $7,500 to $30,000 in regulatory compliance alone, before production, packaging, or shipping.Frequently Asked Questions

Does my Korean ODM handle all three market registrations for me?

Most Korean ODMs handle the Korea-side MFDS notification as part of their service. For the US and EU, you typically need your own regulatory pathway: a US Agent for MoCRA compliance and an EU Responsible Person for CPNP notification. Some larger ODMs have in-house regulatory teams that can assist, but the legal responsibility sits with you as the brand owner in each market.

If my product passes Korean safety testing, is it automatically compliant in the US and EU?

Not automatically. Korean testing to ISO 17516 and ISO 22716 standards covers the microbial and GMP baseline. However, the US and EU may have different requirements for specific ingredients (the EU Annex II and III lists are more restrictive than Korea or the US), different labeling rules, and different heavy metal thresholds. You need market-specific compliance review even if the core formula is identical.What is the difference between a US Agent and an EU Responsible Person?

A US Agent is a contact point for FDA communications on behalf of a foreign facility. They do not take legal liability for the product. An EU Responsible Person takes legal accountability for product safety and regulatory compliance in the EU market. The RP signs off on the CPSR, maintains the PIF, and handles SUE reporting. The EU RP role carries significantly more legal weight and cost.

Can I sell a whitening product in all three markets?

In Korea, whitening is a regulated functional cosmetic claim requiring MFDS review and clinical data. In the US, you can use brightening language for cosmetics, but whitening or bleaching claims may push the product into drug territory under FDA classification. In the EU, brightening claims are permissible for cosmetics as long as they are substantiated and do not imply a therapeutic effect. The same formula may need different claim language and different regulatory pathways depending on the market.How long does a three-market regulatory process take?

If you start all three processes simultaneously: US MoCRA compliance can be ready in four to eight weeks. EU CPSR and CPNP typically take six to twelve weeks. Korea general cosmetic notification takes two to four weeks; functional cosmetic review takes three to six months. Plan for the longest timeline (Korea functional) to set your launch date.

Do I need product liability insurance for all three markets?

It is not legally mandated in all three, but it is effectively required. EU retailers and distributors almost universally require proof of insurance. US retailers and Amazon increasingly require it. Korea is less strict on insurance requirements for imported cosmetics, but it is good practice. Budget $1,000 to $5,000 per year depending on product category and sales volume.What happens if the EU bans an ingredient that Korea and the US still allow?

This happens more often than founders expect. The EU Annex II (prohibited substances) and Annex III (restricted substances) lists are updated regularly and are more restrictive than Korean or US ingredient lists. If the EU restricts an ingredient in your formula, you need a reformulation for the EU market or you drop that market. Your Korean ODM can usually reformulate for a specific market, but reformulation rounds cost $2,000 to $5,000 and add four to eight weeks.

Reviewed for accuracy by ALTA MEET formulation consulting team.

References:

Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products (consolidated text, 2026). MoCRA: Modernization of Cosmetics Regulation Act of 2022 (Public Law 117-328). Korea MFDS Cosmetics Act and Enforcement Decree. ISO 17516:2014, Cosmetics: Microbiology, Limits for microorganisms. ISO 22716:2007, Cosmetics: Good Manufacturing Practices (GMP). USP General Chapters 61 and 62. FDA Draft Guidance: Recommended Maximum Lead Level in Cosmetic Lip Products and Externally Applied Cosmetics (2016). FDA Cosmetics Direct portal and facility registration guidance (updated February 2026). ICH Q1A(R2): Stability Testing of New Drug Substances and Products.